Casey Woodring

So diagnostics grew 6% this quarter. You noted it was a little bit below your expectations.

would be curious to hear how much that forensic TSA 1-timer you called out was in the quarter. Was that baked into the guide

Can you maybe just elaborate on what the financial impact could look like from those contracts

Can you just talk about what LC/MS grew in the quarter and walk through the growth phasing for LC and LC/MS over the course of the year?

within pharma in the quarter, excluding the CDMO, could you break down large molecule versus small molecule growth?

You mentioned academic and government is still weak. We've heard sort of mixed signals from some of the tools vendors

how much your win rate has maybe increased as a result of more of this in-sourcing

you talked about maintaining dry powder for M&A. How should we think about that in relation to some of the comments

Can you just elaborate on that and if that's expected to be a drag on DSA margins next year?

on the forward outlook, how should we think about potential headwinds here for large pharma demand?

Can you just elaborate on what's driving that? What sort of margin differential in the work that's getting canceled looks like?

what your updated expectations are for biotech and DSA this year, just given the weaker funding numbers to start the year?

any quick thoughts on how something like that would impact pharma budgets and that customer group's preclinical drug development spending

can you just elaborate on updated expectations for Radiometer and Leica

The consumables order growth of mid-teens, does that include the pushed out revenue here?

maybe can you just walk through what exactly is offsetting that lower respiratory number for the year?

can you just give us any sense of what orders grew sequentially in 4Q or what book-to-bill was in the quarter?

at what point you'll run into the law of large numbers there. And ultimately, where do you think diagnostics growth will shake out relative to that mid-single-digit range

it's pretty insulated from a lot of this macro noise. So curious how that's contributing to that molecular growth rate moving forward?

I'm just curious on that 12% non-product revenue growth rate, you called out mainly on the breast service component. How did that compare to your expectations in the quarter?

the potential margin benefit once the consolidation is finished and the next gantry is launched and ramped?

can you break out performance in the quarter between US and international customers?

if there's anything baked in there from a supply chain perspective that 19.5% tax rate for '25

I was curious if you could break out the 1Q guide by business segment

curious just how reshoring conversations have trended, if those have picked up at all?

Is the March change in Harmonized Tariff Schedule codes included in that?

Just what's the latest there on the ground in terms of potential stimulus and what that could mean for 2026

the sort of strategy shift towards focusing on the midrange market there that's really driving growth. So just curious if that's a tailwind that you're assuming extends into 2026

maybe just parse out drivers by segment and the outlook in that region for the back half of the year

just curious on timing of when you would expect some of these CapEx announcements to eventually flow through into orders and revenue for you guys

walk us through how you see EBITDA progressing over the course of the year and the cadence of gross margins

Can you walk us through what the guide embeds for data and services revenue in 2026?

just wondering if you're seeing a similar pickup in xF and more of a marketed shift towards liquid?

it looks like Ambry is now an implied 17% top line growth rate if keeping core Tempus at 30%

curious if you'd expect China to return to growth at any point this year?

maybe just walk through where the softness occurred in the quarter. I think we've seen a couple of reports of a weaker microbiology market in China

what's assumed for US academic and government growth in 2026

Curious on how the performance played out relative to your expectations in the quarter

Curious if you could just unpack that for us. How much of that was price? How much was new product contribution in bioseparations

TA. You said that business came back faster than expected. I think you had previously assumed TA would be down 5% in the second half